Brain and Gut Plasticity in Mild TBI or Post-acute COVID Syndrome Following Growth Hormone Therapy
Purpose
Patients with a history of mild traumatic brain injury (mTBI) or post acute sequelae of SARS-CoV-2 (PASC) and abnormal growth hormone secretion, as measured by glucagon stimulation test, will be treated with replacement growth hormone therapy for a period of 6 months (mTBI) or 9 months (PASC). Testing of cognition, exercise, fatigue, brain activation and morphology, body composition and measurements of quality of life will be performed before and after the treatment period. Fecal sampling for characterization of the GI microbiome will occur monthly over the treatment period. Control subjects will be enrolled and will provide fecal samples monthly for 6 months. GI microbiomes will be compared between mTBI patients, PASC patients and controls at baseline as well as over the treatment period.
Conditions
- Traumatic Brain Injury
- Fatigue
- Cognitive Impairment
- COVID-19
Eligibility
- Eligible Ages
- Between 18 Years and 70 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Male or female with a diagnosis of mild TBI. 2. At least 6-month post-injury. 3. Ages 18 to 70 years. 4. Participant is willing and able to give informed consent for participation in the study. mTBI
Exclusion Criteria
- Unable to walk unassisted. 2. Significant heart, liver, kidney, blood or respiratory disease. 3. History of chest pain or coronary heart disease. 4. Uncontrolled Diabetes mellitus. 5. Any history of a recently (12 months) diagnosed cancer other than a skin cancer (excluding melanoma). 6. Recent (within 6 months) treatment with anabolic steroids or corticosteroids. 7. Current alcohol or drug abuse. 8. Premorbid history of psychiatric disorder. 9. Premorbid history of head trauma. 10. Pregnancy or become pregnant during the trial. 11. Coumadin because of the risk of bleeding with daily injections of rhGH. 12. Subjects who are deficient in cortisol or thyroid at screening will be excluded until hormone abnormalities have been corrected. 13. Subjects with chronic pain who are being managed with narcotics will be excluded as the effects of central nervous system depressants may interfere with study test results. 14. Subjects with a history of inflammatory bowel disease, Celiac disease or active diverticular disease. 15. Other medical condition or medication administration deemed exclusionary by the study investigators. Control Inclusion criteria 1. Ages 18 to 70 years. 2. Participant is willing and able to give informed consent for participation in the study. Control Exclusion criteria 1. Significant heart, liver, kidney, blood or respiratory disease. 2. Uncontrolled Diabetes mellitus. 3. Any history of a recently (12 months) diagnosed cancer other than a skin cancer (excluding melanoma). 4. Recent (within 6 months) treatment with anabolic steroids or corticosteroids. 5. Current alcohol or drug abuse. 6. Premorbid history of psychiatric disorder. 7. Premorbid history of head trauma. 8. Pregnancy or become pregnant during the trial. 9. Subjects who are deficient in thyroid at screening will be excluded until thyroid hormone is replaced. 10. Subjects with a history of inflammatory bowel disease, Celiac disease or active diverticular disease. 11. Other medical condition or medication administration deemed exclusionary by the study investigators. PASC Inclusion criteria 1. Male or female with a history of COVID with diagnosis confirmed by PCR test. 2. Minimum of 6 months since diagnosis of COVID by PCR test. 3. Ages 18 to 70 years. 4. Score of 3 or higher on any question 1-3 of the Brief Fatigue Inventory (BFI) questionnaire. 5. Participant is willing and able to give informed consent for participation in the study. PASC Exclusion criteria 1. Current COVID infection. 2. Unable to walk unassisted. 3. Significant heart, liver, kidney, blood or respiratory disease as determined by Principal Investigator. 4. Uncontrolled diabetes mellitus. 5. Any history of a recently (12 months) diagnosed cancer other than a skin cancer (excluding melanoma). 6. Current alcohol or drug abuse. 7. History of psychosis. 8. Pregnancy or become pregnant during the trial. 9. Subjects who are being managed with narcotics will be excluded as the effects of central nervous system depressants may interfere with study test results. 10. Other medical condition or medication administration deemed exclusionary by the study investigators.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Non-Randomized
- Intervention Model
- Parallel Assignment
- Intervention Model Description
- mTBI patients will be in the growth hormone arm PASC patients will be in the growth hormone arm Control subjects will be in the control arm
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental mTBI subjects |
mTBI subjects will receive recombinant human growth hormone replacement therapy daily for 6 months. Drug: recombinant human growth hormone (rhgH); somatropin, Genotropin Dose: month 0 - month 1 will be dosed at 0.4 mg / day month 1 - month 6 will be dosed at 0.6 mg / day |
|
|
No Intervention Household Control Subjects |
household control subjects will not receive any intervention. |
|
|
Experimental PASC subjects |
PASC subjects will receive recombinant human growth hormone replacement therapy daily for 9 months. Drug: recombinant human growth hormone (rhgH); somatropin, Genotropin Dose: month 0 - month 1 will be dosed at 0.4 mg / day month 1 - month 9 will be dosed at 0.6 mg / day |
|
More Details
- Status
- Completed
- Sponsor
- The University of Texas Medical Branch, Galveston
Study Contact
Detailed Description
The investigators will study subjects (aged 18-70 years) with a history of mild TBI (n=25), post-acute sequelae of SARS-CoV-2 (PASC) (n=25)and healthy controls (n=25). mTBI subjects will undergo a 6-month intervention of rhGH therapy. PASC subjects will undergo a 9-month intervention of rhGH therapy. Controls will be asked to participate in questionnaires, blood draws (amino acid analysis), and fecal sampling (GI microbiome analysis). Controls will not receive any growth hormone treatment. mTBI group All patients presenting with a prior mTBI will undergo a phone pre-screen including the Brief Fatigue Inventory (BFI) questions 1-3. If they score ≥ 3 on any BFI questions 1-3, and are interested in participating in the study, they will be scheduled for a formal consenting and medical screening at the UTMB Clinical Research Center (CRC). During the medical screening, eligibility will be confirmed and a glucagon stimulation test (GST) will be performed. A glucagon stimulation with a growth hormone peak of <10 ng/mL is required to qualify for enrollment. PASC group All patients presenting with PASC will undergo a phone pre-screen including the Brief Fatigue Inventory (BFI) questions 1-3. If they score ≥ 3 on any BFI questions 1-3, and are interested in participating in the study, they will be scheduled for a formal consenting and medical screening at the UTMB Clinical Research Center (CRC). During the medical screening, eligibility will be confirmed and a glucagon stimulation test (GST) will be performed. A glucagon stimulation with a growth hormone peak of <10 ng/mL is required to qualify for enrollment. Control group All controls will undergo a phone pre-screen and if interested in participating in the study, will be scheduled for a formal consenting and medical screening at the UTMB Clinical Research Center (CRC). Experimental Protocol. mTBI Group Before and at completion (month 6) of the rhGH intervention, mTBI subjects will report to the UTMB Institute for Translational Sciences (ITS) Clinical Research Center (CRC) for testing, which will consist of cognitive function assessment (MoCA), determination of brain morphology and connectivity using fMRI, determination of lean mass and fat mass using DEXA, resting energy expenditure, functional testing including leg strength and 6 minute walk test, fatigue measurements, and questionnaires of mood and quality of life, gastrointestinal health, sleep, and food preferences. Blood sampling for measurement of amino acid levels, hormones, and metabolites will be drawn before and 90 minutes (+/- 10 minutes) after a standardized meal. In addition, fecal samples for analysis of the GI microbiome will be collected monthly for the duration of the study. Insulin Growth Factor 1 (IGF-1) levels will monitored at a month 1 safety visit for all mTBI subjects. The month 1 safety visit will occur +/- 5 days from the expected date based on the baseline study visit. The monthly fecal sampling will occur +/- 7 days from the expected date based on the baseline study visit. The month 6 post study will occur +/- 7 days from the expected date based on the baseline study visit. A member of the study team will contact the subject each month to coordinate fecal sample transport to UTMB, check for adverse events and overall well-being, and ensure compliance and ongoing consent. PASC Group Before and at month 6 of the rhGH intervention, PASC subjects will report to the UTMB Institute for Translational Sciences (ITS) Clinical Research Center (CRC) for testing, which will consist of cognitive function assessment (MoCA), determination of lean mass and fat mass using DEXA, resting energy expenditure, functional testing including leg strength and 6 minute walk test, fatigue measurements, and questionnaires of mood and quality of life, gastrointestinal health, sleep, and food preferences. Blood sampling for measurement of amino acid levels, hormones, and metabolites will be drawn before and 90 minutes (+/- 10 minutes) after a standardized meal. In addition, fecal samples for analysis of the GI microbiome will be collected monthly for the duration of the study. Insulin Growth Factor 1 (IGF-1) levels will monitored at a month 1 safety visit for all mTBI subjects. The month 1 safety visit will occur +/- 5 days from the expected date based on the baseline study visit. The monthly fecal sampling will occur +/- 7 days from the expected date based on the baseline study visit. The month 6 post study will occur +/- 7 days from the expected date based on the baseline study visit. PASC subjects will continue on rhGH treatment for an additional 3 months. GI microbiome sampling and questionnaires will occur at month 9 and month 12. PASC subjects will have an repeat glucagon stimulation test (GST) to determine growth hormone status at month 12. A member of the study team will contact the subject each month to coordinate fecal sample transport to UTMB, check for adverse events and overall well-being, and ensure compliance and ongoing consent. Control group Before and at month 6, controls will report to the UTMB Institute for Translational Sciences (ITS) Clinical Research Center (CRC) for testing, which will consist of questionnaires of food preferences and gastrointestinal health and blood sampling for measurement of amino acid levels, hormones, and metabolites which will be drawn before and 90 minutes (+/ 10 minutes) after a standardized meal. In addition, fecal samples for the analysis of the GI microbiome will be collected monthly for the duration of the study, as well as questionnaire assessing gastrointestinal health. The monthly fecal sampling will occur +/- 7 days from the expected date based on the baseline study visit. The post study (month 6) will occur +/- 7 days from the expected date based on the baseline study visit. A member of the study team will contact the subject each month to coordinate fecal sample transport to UTMB, check for adverse events and overall well-being, and ensure compliance and ongoing consent.